<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03728699</url>
  </required_header>
  <id_info>
    <org_study_id>2018NTLS107</org_study_id>
    <secondary_id>HM2018-23</secondary_id>
    <nct_id>NCT03728699</nct_id>
  </id_info>
  <brief_title>Microbiota Changes in Acute Myeloid Leukemia Patients Undergoing Intensive Chemotherapy</brief_title>
  <official_title>Microbiota Changes in Acute Myeloid Leukemia Patients Undergoing Intensive Chemotherapy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Masonic Cancer Center, University of Minnesota</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Masonic Cancer Center, University of Minnesota</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a prospective, observational study to collect stool and blood from acute myeloid
      leukemia patients undergoing intensive chemotherapy.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">January 2, 2018</start_date>
  <completion_date type="Anticipated">February 2025</completion_date>
  <primary_completion_date type="Anticipated">February 2025</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Abundance of Phyla</measure>
    <time_frame>Day 28</time_frame>
    <description>Abundance in stool and circulating microbiota during intensive chemotherapy in patients with acute myeloid leukemia (AML), measured by16S rRNA gene profiling of biospecimens using the Illumina MiSeq platform</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Abundance of Genera</measure>
    <time_frame>Day 28</time_frame>
    <description>Abundance in stool and circulating microbiota during intensive chemotherapy in patients with acute myeloid leukemia (AML), measured by16S rRNA gene profiling of biospecimens using the Illumina MiSeq platform</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Circulating Microbiota Diversity (Blood)</measure>
    <time_frame>Day 28</time_frame>
    <description>Describe circulating microbiota diversity over the course of treatment</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Microbiota Diversity (Stool)</measure>
    <time_frame>Day 28</time_frame>
    <description>Describe stool microbiota diversity over the course of treatment</description>
  </secondary_outcome>
  <enrollment type="Anticipated">100</enrollment>
  <condition>Acute Myeloid Leukemia</condition>
  <intervention>
    <intervention_type>Diagnostic Test</intervention_type>
    <intervention_name>Sample Collection Blood</intervention_name>
    <description>Collected from each patient twice weekly.</description>
  </intervention>
  <intervention>
    <intervention_type>Diagnostic Test</intervention_type>
    <intervention_name>Stool Sample</intervention_name>
    <description>Collected from each patient twice weekly.</description>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Adult patients with acute myeloid leukemia (new diagnosis, refractory, or relapsed)
        undergoing any intensive chemotherapy with expected inpatient stay of ~4 weeks.
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Adults (ages 18 - 99 years) undergoing inpatient intensive chemotherapy for newly
             diagnosed, refractory, or relapsed AML. Patients may or may not have been exposed to
             any type of therapy before.

          -  Any intensive chemotherapy regimen defined as a planned ~4 week inpatient stay.
             Chemotherapy may be delivered for any number of days and on any schedule. Patients may
             be discharged from the hospital sooner than 4 weeks if the treating physician choose
             so, but the expectation at the initiation of chemotherapy must be ~4 weeks of
             inpatient stay, as is typical.

          -  Able to provide written voluntary consent before performance of any study related
             procedure.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>99 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Timothy Krepski, RN</last_name>
    <phone>612-273-2800</phone>
    <email>tkrepsk1@fairview.org</email>
  </overall_contact>
  <location>
    <facility>
      <name>Masonic Cancer Center at University of Minnesota</name>
      <address>
        <city>Minneapolis</city>
        <state>Minnesota</state>
        <zip>55455</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>February 2020</verification_date>
  <study_first_submitted>October 31, 2018</study_first_submitted>
  <study_first_submitted_qc>October 31, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">November 2, 2018</study_first_posted>
  <last_update_submitted>February 13, 2020</last_update_submitted>
  <last_update_submitted_qc>February 13, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">February 17, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>AML</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Leukemia</mesh_term>
    <mesh_term>Leukemia, Myeloid</mesh_term>
    <mesh_term>Leukemia, Myeloid, Acute</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

